Cancer Biomarkers
A section of Cancers (ISSN 2072-6694).
Section Information
In the current era of precision medicine, cancer biomarkers provide critical data for predicting responses to therapies, generating prognoses of disease outcomes, and in determining oncogenic risk. Biomarkers are increasingly important as companions for drug discovery and development, and can help guide clinical decision-making. This section of Cancers aims to rapidly publish contributions on all aspects of Cancer Biomarkers. We encourage the submission of manuscripts that provide novel biomarkers, systematic reviews, and papers that report significant advances in cancer biomarkers. Topics include, but are not limited to:
- Genomic signatures
- RNA biomarkers
- miRNA biomarkers
- DNA biomarkers
- Protein biomarkers
- Metabolomic biomarkers
- Mutational biomarkers
- Circulating tumor cell (CTC) biomarkers
- Cellular biomarkers
- Imaging biomarkers
- Clinical biomarkers
- Biomarkers of drug response
- Biomarkers of genetic predisposition to cancer
- Biomarkers of cancer outcomes
Editorial Board
Topical Advisory Panel
Special Issues
Following special issues within this section are currently open for submissions:
- Sarcopenia and Frailty as a Prognostic/Outcome Biomarker of Urological Cancer Patients (Deadline: 15 October 2023)
- Ovarian Cancer Proliferation and Progression (Deadline: 20 October 2023)
- Views and Perspectives of Cutaneous Squamous Cell Carcinoma (Deadline: 31 October 2023)
- miRNA in Colorectal Cancer (Deadline: 31 October 2023)
- The Role of Long Non-coding RNA in Solid Tumors (Deadline: 31 October 2023)
- Innovation in the Treatment of Thoracic Cancers (Deadline: 31 October 2023)
- Novel Biomarkers in Acute Myeloid Leukemia (AML) (Deadline: 31 October 2023)
- Advances in Translational Research for Soft Tissue Sarcomas (Deadline: 15 November 2023)
- Liquid Biopsy for Lung Cancer Treatment (Deadline: 15 November 2023)
- Novel Markers in Lymphoma (Deadline: 15 November 2023)
- Circulating microRNAs as Biomarkers in Cancer Prognosis (Deadline: 15 November 2023)
- Genome Sequencing of Cancer: Identifying Targets and Biomarkers for Therapy (Deadline: 25 November 2023)
- Biomarkers for Neuroendocrine Neoplasms (Deadline: 30 November 2023)
- Glycosylation in Cancer—Biomarkers and Targeted Therapies (Deadline: 30 November 2023)
- Possible Biomarkers in Oral Tumors and Their Clinical Significance (Deadline: 30 November 2023)
- Cell-Free DNA as Prognostic and Predictive Biomarker in Solid Cancers (Deadline: 30 November 2023)
- Clinical Significance of cfRNAs as Tumor Biomarkers (Deadline: 15 December 2023)
- Prognostic Biomarkers of Lung Cancer (Deadline: 31 December 2023)
- Hallmark Properties and Behind-the-Scenes Role of Non-coding RNAs in Gastrointestinal Cancers’ Onset, Progression and Metastasis (Deadline: 31 December 2023)
- Biomarkers in Breast Cancer: Recent Advances and Challenges (Deadline: 31 December 2023)
- Advances in Follicular Lymphoma (Deadline: 31 December 2023)
- Dynamics of Cancer: Complexity and Hierarchy on Cancer Cells and Tissues (Deadline: 31 December 2023)
- Biomarker in Urologic Cancer (Deadline: 31 December 2023)
- Novel Diagnostic and Therapeutic Approaches in Diffuse Gliomas (Deadline: 31 December 2023)
- MRI and PET Imaging in Neuro-Oncology—Current Developments and Clinical Translation (Deadline: 31 January 2024)
- Monitoring Treatment Response of Biomarkers in Cancer (Deadline: 31 January 2024)
- Stem Cells in Oral Cancer (Deadline: 10 February 2024)
- Targeting the PI3K/AKT/mTOR Pathway in Cancer: Mechanisms and Advances in Clinical Trials (Deadline: 15 February 2024)
- Uveal Melanoma Biology, Biomarkers for Metastatic Risk and Personalized Treatment (Deadline: 24 February 2024)
- Head and Neck Cancers—Novel Approaches and Future Outlook (Deadline: 29 February 2024)
- The Biomarkers and Detection of Head and Neck Cancer (Volume II) (Deadline: 29 February 2024)
- Novel Biomarkers in Non-small Cell Lung Cancer (NSCLC) (Deadline: 1 March 2024)
- New Biomarkers in Cancers (Volume II) (Deadline: 15 March 2024)
- Novel Biomarkers of Hepatobiliary Tumors (Deadline: 31 March 2024)
- Prognostic Biomarkers of Head and Neck Cancer (Deadline: 31 March 2024)
- Biomarkers in Renal Cell Cancer (Deadline: 31 March 2024)
- Cancer Biomarkers: Recent Progress, Innovations and Future Clinical Implications (Deadline: 14 April 2024)
- Advances in Soft Tissue and Bone Sarcoma (Deadline: 30 April 2024)
- 2nd Edition: Minimal Residual Disease of Cancers (Deadline: 30 April 2024)
- Novel Prognostic Biomarkers in Human Cancers: From Discovery to Application (Deadline: 15 May 2024)
- Feature Papers in Section "Cancer Biomarkers" in 2023–2024 (Deadline: 31 May 2024)
- Circulating Cancer Biomarkers: Progress, Challenges and Opportunities (Deadline: 31 May 2024)
- Breast Cancer Biomarkers and Clinical Translation (Deadline: 31 May 2024)
- Chronic Lymphocytic Leukemia: Identification of Novel Prognostic Markers and Their Clinical Application (Deadline: 10 June 2024)
- Predictive Biomarkers for Colorectal Cancer (Deadline: 21 June 2024)
- Biomarkers for the Early Detection and Treatment of Cancers (Deadline: 30 June 2024)
- The Estrogen Receptor and Its Role in Cancer (Deadline: 15 September 2024)
- PTEN: Regulation, Signalling and Targeting in Cancer (Deadline: 31 December 2024)
Topical Collections
Following topical collections within this section are currently open for submissions:
- Advances in Cancer Radiotherapy
- Biomarkers for Detection and Prognosis of Prostate Cancer
- Biomarkers of Thyroid Cancer
- Cancer Biomarkers
- Cancer Biomarkers in Body Fluids
- The Biomarkers for the Diagnosis and Prognosis in Cancer
- The Molecular Predictive and Prognostic Biomarkers in Breast Cancer
- The Role of Non-coding RNA in Cancer
